Summary

Biologics Market – Scope of Report
TMR’s report on the global biologics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global biologics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global biologics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the biologics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global biologics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global biologics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global biologics market.

The report delves into the competitive landscape of the global biologics market. Key players operating in the global biologics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global biologics market profiled in this report.

Key Questions Answered in Global biologics Market Report
• What is the sales/revenue generated by biologics across all regions during the forecast period?
• What are the opportunities in the global biologics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Biologics Market – Research Objectives and Research Approach
The comprehensive report on the global biologics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global biologics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global biologics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Biologics Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Biologics Market Analysis and Forecasts, 2017–2031
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Key Industry Events
5.2. Porter's Five Forces Analysis
5.3. Disease Prevalence & Incidence Rate by Region/Globally
5.4. Regulatory Scenario by Region/Globally
5.5. Value Chain Analysis
5.6. COVID 19 Impact Analysis
6. Global Biologics Market Analysis and Forecasts, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Recombinant Proteins
6.3.3. Vaccines
6.3.4. Cell & Gene Therapy
6.3.5. Others
6.4. Market Attractiveness By Product
7. Global Biologics Market Analysis and Forecasts, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2017–2031
7.3.1. Oncology
7.3.2. Autoimmune & Immunological Disorders
7.3.3. Hematological Disorders
7.3.4. Infectious Diseases
7.3.5. Others
7.4. Market Attractiveness By Application
8. Global Biologics Market Analysis and Forecasts, By Manufacturing
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Manufacturing, 2017–2031
8.3.1. Outsourced
8.3.2. In-house
8.4. Market Attractiveness By Manufacturing
9. Global Biologics Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Biologics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Product, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Recombinant Proteins
10.2.3. Vaccines
10.2.4. Cell & Gene Therapy
10.2.5. Others
10.3. Market Value Forecast By Application, 2017–2031
10.3.1. Oncology
10.3.2. Autoimmune & Immunological Disorders
10.3.3. Hematological Disorders
10.3.4. Infectious Diseases
10.3.5. Others
10.4. Market Value Forecast By Manufacturing, 2017–2031
10.4.1. Outsourced
10.4.2. In-house
10.5. Market Value Forecast By Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By Manufacturing
10.6.4. By Country
11. Europe Biologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Recombinant Proteins
11.2.3. Vaccines
11.2.4. Cell & Gene Therapy
11.2.5. Others
11.3. Market Value Forecast By Application, 2017–2031
11.3.1. Oncology
11.3.2. Autoimmune & Immunological Disorders
11.3.3. Hematological Disorders
11.3.4. Infectious Diseases
11.3.5. Others
11.4. Market Value Forecast By Manufacturing, 2017–2031
11.4.1. Outsourced
11.4.2. In-house
11.5. Market Value Forecast By Country, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By Manufacturing
11.6.4. By Country/Sub-region
12. Asia Pacific Biologics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Product, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Recombinant Proteins
12.2.3. Vaccines
12.2.4. Cell & Gene Therapy
12.2.5. Others
12.3. Market Value Forecast By Application, 2017–2031
12.3.1. Oncology
12.3.2. Autoimmune & Immunological Disorders
12.3.3. Hematological Disorders
12.3.4. Infectious Diseases
12.3.5. Others
12.4. Market Value Forecast By Manufacturing, 2017–2031
12.4.1. Outsourced
12.4.2. In-house
12.5. Market Value Forecast By Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of APAC
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By Manufacturing
12.6.4. By Country/Sub-region
13. Latin America Biologics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.2. Recombinant Proteins
13.2.3. Vaccines
13.2.4. Cell & Gene Therapy
13.2.5. Others
13.3. Market Value Forecast By Application, 2017–2031
13.3.1. Oncology
13.3.2. Autoimmune & Immunological Disorders
13.3.3. Hematological Disorders
13.3.4. Infectious Diseases
13.3.5. Others
13.4. Market Value Forecast By Manufacturing, 2017–2031
13.4.1. Outsourced
13.4.2. In-house
13.5. Market Value Forecast By Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of LATAM
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By Manufacturing
13.6.4. By Country/Sub-region
14. Middle East & Africa Biologics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.2. Recombinant Proteins
14.2.3. Vaccines
14.2.4. Cell & Gene Therapy
14.2.5. Others
14.3. Market Value Forecast By Application, 2017–2031
14.3.1. Oncology
14.3.2. Autoimmune & Immunological Disorders
14.3.3. Hematological Disorders
14.3.4. Infectious Diseases
14.3.5. Others
14.4. Market Value Forecast By Manufacturing, 2017–2031
14.4.1. Outsourced
14.4.2. In-house
14.5. Market Value Forecast By Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of MEA
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Application
14.6.3. By Manufacturing
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Share Analysis By Company (2022)
15.2. Company Profiles
15.2.1. AbbVie, Inc.
15.2.1.1. Company Overview
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Business Strategies
15.2.1.5. Recent Developments
15.2.2. Amgen
15.2.2.1. Company Overview
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Business Strategies
15.2.2.5. Recent Developments
15.2.3. AstraZeneca
15.2.3.1. Company Overview
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Business Strategies
15.2.3.5. Recent Developments
15.2.4. Bristol-Myers Squibb Company
15.2.4.1. Company Overview
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Business Strategies
15.2.4.5. Recent Developments
15.2.5. Eli Lilly
15.2.5.1. Company Overview
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Business Strategies
15.2.5.5. Recent Developments
15.2.6. Gilead Sciences, Inc.
15.2.6.1. Company Overview
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Business Strategies
15.2.6.5. Recent Developments
15.2.7. GlaxoSmithKline
15.2.7.1. Company Overview
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Business Strategies
15.2.7.5. Recent Developments
15.2.8. Johnson & Johnson Services, Inc.
15.2.8.1. Company Overview
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Business Strategies
15.2.8.5. Recent Developments
15.2.9. Merck & Co. Inc.
15.2.9.1. Company Overview
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. Business Strategies
15.2.9.5. Recent Developments
15.2.10. Novartis AG
15.2.10.1. Company Overview
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. Business Strategies
15.2.10.5. Recent Developments
15.2.11. Pfizer, Inc.
15.2.11.1. Company Overview
15.2.11.2. Financial Overview
15.2.11.3. Product Portfolio
15.2.11.4. Business Strategies
15.2.11.5. Recent Developments
15.2.12. F. Hoffmann-La Roche Ltd
15.2.12.1. Company Overview
15.2.12.2. Financial Overview
15.2.12.3. Product Portfolio
15.2.12.4. Business Strategies
15.2.12.5. Recent Developments